Kevin V. Chow

Kevin V. Chow

Auto-generated profile, based on publicly available information

Kevin V. Chow

The Royal Melbourne Hospital, Parkville, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2014 in Nephrology
Verified
Journal Article
Open access
PDF file
TBThomas D Barbour
Thomas D Barbour
ACAmy Crosthwaite
Amy Crosthwaite
KCKevin Chow
Kevin Chow
MFMoira J Finlay
Moira J Finlay
NBNathan Better
Nathan Better
SCSolomon J Cohney
Solomon J Cohney
Antiphospholipid syndrome (APS) may occur in isolation or in association with systemic lupus erythematosus (SLE), with the potential to cause renal failure via several distinct pathologies. Renal transplantation in the presence ofAPScarries a risk of early graft loss from arterial or venous thrombosis, or thrombotic microangiopathy (TMA). Whilst perioperative anticoagulation reduces the risk of large vessel thrombosis, it may result in significant haemorrhage, and its efficacy in preventing post‐transplantTMAis uncertain. Here, we report a patient with end‐stage kidney disease (ESKD) due to lupus nephritis andAPS, in whom allograftTMAdeveloped soon after transplantation despite partial anticoagulation.TMAresolved with plasma exchange‐based therapy albeit with some irreversible graft damage and renal impairment. We discuss the differential diagnosis of post‐transplantTMA, and current treatment options.

28 July 2021 in Transplant International
Verified
Journal Article
Closed access
PDF file
KMKylie Martin
Kylie Martin
LCLinda Cantwell
Linda Cantwell
KBKatherine A. Barraclough
Katherine A. Barraclough
MLMichael Lian
Michael Lian
RMRosemary Masterson
Rosemary Masterson
KCKevin V. Chow
Kevin V. Chow
Background The optimum approach toward immunosuppression withdrawal following kidney transplant failure is unclear. Prolonged weaning may be associated with reduced sensitisation, less graft nephrectomy and greater likelihood of re-transplantation, but conversely increased risk of infection, malignancy and death. Methods We conducted a single centre retrospective analysis of patients experiencing graft failure between 2007-2017, comparing rates of sensitisation, re-transplantation, nephrectomy, infection, malignancy and death between patients who had immunosuppression weaned over 180 days. Results Patient survival after immunosuppression withdrawal over 180 days was 73.3%, 72.1% and 80.4% respectively (p=0.35), with no differences in cPRA (80.06 vs. 81.21 vs. 85.42, p=0.66) or re-transplantation rate (24/31 (77.4%) vs. 21/35 (60.0%) vs. 22/36 (61.1%), p=0.13). There was significantly less nephrectomy after late immunosuppression cessation (10/42 (23.8%) vs. 7/42 (16.7%) vs. 3/43 (7.0%), p=0.01) but no differences in infections or malignancy. On competing risk regression (death as competing risk) controlling for cofactors including age, nephrectomy and rejection, prolonged immunosuppression did not predict likelihood of re-transplantation (SHR 1.000, p=0.88). Conclusions Prolonged immunosuppression withdrawal does not reduce sensitisation or improve re-transplantation rates but is associated with less nephrectomy. Immunosuppression withdrawal should be tailored to individual circumstances after graft failure.

15 October 2025 in American Journal of Transplantation
Verified
Journal Article
Open access
JMJeremy S. McComish
Jeremy S. McComish
JBJessica Brewster
Jessica Brewster
ECEmma Carreiro
Emma Carreiro
KCKevin Chow
Kevin Chow
CHChristopher Hogan
Christopher Hogan
JDJames Daly
James Daly
De novo blood donor-specific human leukocyte antigen (HLA) antibodies (bDSA) from red cell transfusions can complicate solid organ transplantation, but the incidence rate is uncertain. We conducted a prospective observational study to assess the cumulative incidence rate of de novo bDSA in a cohort of patients with chronic kidney disease and no prior transplant, patients with prior kidney transplants (with or without continuing immunosuppression), and a general patient population. HLA antibody testing was performed before and 6 to 8 weeks after transfusion, with patient and blood donor typing. De novo HLA class 1 bDSA were detected in 10.8% (12 of 111) participants at a "weak" cutoff and in 7.2% (8 of 111) at a "moderate/strong" cutoff. De novo HLA class 2 bDSA were detected in 0.9% (1 of 111) at both cutoffs. Risk factors identified for HLA class 1 de novo bDSA included female sex (P < .001) and pretransfusion HLA antibodies (P = .02). The posttransplant group had low de novo bDSA (1 of 37, 2.7%). Additional testing suggested anamnestic (rather than de novo) responses in some participants. Red cell transfusions are associated with de novo bDSA, especially to HLA class 1 antigens, and measures to prevent sensitization, including selecting donors to avoid mismatches, may be warranted for some groups.

15 April 2025 in JCI Insight
Verified
Journal Article
Open access
PDF file
PHPhilip F. Halloran
Philip F. Halloran
JCJessica Chang
Jessica Chang
MMMartina Mackova
Martina Mackova
KMKatelynn S. Madill-Thomsen
Katelynn S. Madill-Thomsen
EAEnver Akalin
Enver Akalin
CHChristian Hinze
Christian Hinze
Background. Expression of acute kidney injury–associated (AKI-associated) transcripts in kidney transplants may reflect recent injury and accumulation of epithelial cells in “failed repair” states. We hypothesized that the phenomenon of failed repair could be associated with deterioration and failure in kidney transplants. Methods. We defined injury-induced transcriptome states in 4,502 kidney transplant biopsies injury-induced gene sets and classifiers previously developed in transplants. Results. In principal component analysis (PCA), PC1 correlated with both acute and chronic kidney injury and related inflammation and PC2 with time posttransplant. Positive PC3 was a dimension that correlated with epithelial remodeling pathways and anticorrelated with inflammation. Both PC1 and PC3 correlated with reduced survival, with PC1 effects strongly increasing over time whereas PC3 effects were independent of time. In this model, we studied the expression of 12 “new” gene sets annotated in single-nucleus RNA-sequencing studies of epithelial cells with failed repair in native kidneys. The new gene sets reflecting epithelial-mesenchymal transition correlated with injury PC1 and PC3, lower estimated glomerular filtration rate, higher donor age, and future failure as strongly as any gene sets previously derived in transplants and were independent of nephron segment of origin and graft rejection. Conclusion. These results suggest 2 dimensions in the kidney transplant response to injury: PC1, AKI-induced changes, failed repair, and inflammation; and PC3, a response involving epithelial remodeling without inflammation. Increasing kidney age amplifies PC1 and PC3. Trial registration. INTERCOMEX (ClinicalTrials.gov NCT01299168); Trifecta-Kidney (ClinicalTrials.gov NCT04239703). Funding. Genome Canada; Natera, Inc.; and Thermo Fisher Scientific.

14 November 2025 in Frontiers in Transplantation
Verified
Journal Article
Open access
PDF file
AZAngela Zeng
Angela Zeng
KBKatherine Barraclough
Katherine Barraclough
MLMichael Lian
Michael Lian
RMRosemary Masterson
Rosemary Masterson
PHPeter Hughes
Peter Hughes
KCKevin V. Chow
Kevin V. Chow
Background: Cytomegalovirus (CMV) causes significant morbidity and mortality following kidney transplantation. Late CMV infection (≥2 years post-transplant) is uncommon, and its risk factors and outcomes may differ from earlier infection. Methods: We conducted a single-centre retrospective study of kidney transplant recipients between 2009 and 2019. Patients were grouped by CMV status: no infection, early infection (<2 years post-transplant), and late infection (≥2 years post-transplant). Clinical characteristics and outcomes were compared. Results: Donor-positive/recipient-negative (D+/R−) serostatus was observed in 105/710 (14.8%) patients without CMV, 28/42 (66.7%) with early CMV, and 2/28 (7.1%) with late CMV ( p < 0.001). Prior rejection occurred in 5.9%, 16.7%, and 10.7% respectively ( p = 0.017). Median serum creatinine was 113.0, 127.5, and 219.5 µmol/L respectively ( p < 0.001). CMV serostatus was significantly associated with early infection ( p < 0.001), while only serum creatinine was associated with late infection ( p = 0.003). Trends were seen toward better one-year patient survival (97.6% vs. 85.7%, p = 0.051) and graft survival (88.1% vs. 71.4%, p = 0.073) after early vs. late infection. Conclusions: Risk factors for CMV infection differ by timing post-transplant. Renal dysfunction may be a key predictor of late infection. identifying at-risk patients may support targeted surveillance and improve long-term outcomes.

5 May 2026 in JCI Insight
Verified
Journal Article
Open access
PDF file
KMKatelynn Madill-Thomsen
Katelynn Madill-Thomsen
MMMartina Mackova
Martina Mackova
JCJessica Chang
Jessica Chang
EAEnver Akalin
Enver Akalin
TATarek Alhamad
Tarek Alhamad
PHPhilip F. Halloran
Philip F. Halloran
Because older donor age is a major concern when considering kidneys for potential transplantation, we explored the actual effect of donor age on the features of kidneys that have been transplanted. We studied the correlations of donor age with molecular injury and rejection scores in 4,502 kidney transplant biopsies assessed by microarrays as well as function and postbiopsy survival. We used multivariable analyses to correct for the correlations of donor age with other predictive variables: recipient age, time of biopsy after transplant, and deceased versus living donors. Older donor age correlated with lower glomerular filtration rate (GFR) and increased acute and chronic injury transcripts but had no effect on rejection, which was anticorrelated with recipient age. Acute injury transcripts peaked immediately after transplant and regressed. Older donor age had little effect on acute molecular injury immediately after transplant but strongly increased molecular injury scores at later times, peaking about 1-year after transplant, indicating that older age does not increase molecular injury but increases failed repair after injury. As expected, older donor age correlated with increased chronic injury and lower GFR, evident from the earliest time after transplant, pretransplant aging. However, despite substantial age-related effects, the quantitative contribution of donor aging to molecular injury, function, and survival was very small.